Syndax presents positive revuforj® (revumenib) data in acute leukemias from multiple trials, including the save combination and augment-101 trials, at 66th ash annual meeting

–        82% orr (27 of 33 pts) and 48% cr/crh (16 of 33 pts) in save trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in r/r aml – –        64% orr (62 of 97 pts) and 23% cr/crh (22 of 97 pts) with high rates of mrd negativity and ability to proceed to hsct in expanded dataset of ph 2 r/r kmt2ar acute leukemia patients in augment-101 – –         responses were rapid, durable and observed across all major subgroups in expanded dataset ofph 2 r/r kmt2ar acute leukemia patients in augment-101 – –         latest data highlight the compelling clinical profile of revumenib and support advancement into combination trials in the frontline setting – waltham, mass. , dec. 7, 2024 /prnewswire/ -- syndax pharmaceuticals (nasdaq: sndx), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today presented positive data from multiple trials of revuforj® (revumenib) as a single-agent and in combination with standard of care agents in patients with acute leukemias in oral sessions at the 66th american society of hematology (ash) annual meeting being held in san diego, december 7-10, 2024.
ASH Ratings Summary
ASH Quant Ranking